Sun Pharma

InSite Vision, Sun Pharma enter into $48M merger agreement

Wednesday, September 16, 2015

InSite Vision and a subsidiary of Sun Pharmaceutical Industries have entered into a merger agreement under which an indirect wholly owned subsidiary of Sun Pharma will acquire InSite in an all-cash transaction for $0.35 per share, or approximately $48 million in aggregate equity value, on a fully diluted basis. The transaction has been approved by the boards of directors of both InSite and the Sun Pharma subsidiary, and will be completed by means of a tender offer.

[Read More]

Sun Pharma closes merger deal with Ranbaxy

Thursday, March 26, 2015

Sun Pharmaceutical Industries has begun the integration of Ranbaxy‘s business following the successful closure of its merger. The integration, planned by Sun Pharma since the announced merger in April 2014, will focus on supporting strong growth. According to Sun Pharma, the merger has fortified its position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian pharma company.

[Read More]

Sun Pharma, Taro terminate proposed merger

Friday, February 8, 2013

Sun Pharmaceutical Industries, an India-based specialty pharmaceutical company, and Taro Pharmaceutical Industries, a multinational, science-based pharmaceutical company, have  mutually  agreed  to  terminate  their  merger  agreement,  announced  in  August  2012,  pursuant  to which all shareholders of Taro (other than Sun Pharma and its affiliates) would have received a cash payment of $39.50 per share upon the closing of the merger.

[Read More]